Sarcoma  >>  Vigil (gemogenovatucel-T)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vigil (gemogenovatucel-T) / Gradalis
NCT02511132: A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Completed
2b
22
US
Vigil, formerly known as FANG™, bi-shRNAfurin and GMCSF Autologous Tumor Cell Immunotherapy, Temozolomide, TEMODAR, Irinotecan, CAMPTOSAR, Gemcitabine, GEMZAR, Docetaxel, TAXOTERE
Gradalis, Inc.
Ewing's Sarcoma
11/18
12/20

Download Options